close
Add to watchlist
Telik Inc (TELK) Healthcare, Biotechnology & Drugs
Telik, Inc., a clinical stage drug development company, focuses on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the discovery of small molecule drug candidates. The company was founded in 1988 and is based in Palo Alto, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.17 |
| Volume | 243720 |
| Volume Avg | 745412 |
| 52 Week High | 1.01 |
| 52 Week Low | 0.13 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.22 |
| EPS change Q/Q | -100% |
| EPS change Q/Q Yr ago | -125% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -4.35% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |